Chemical inhibitors of LOC623272 may function through various pathways, potentially leading to its functional inhibition. LY294002 and Wortmannin, as PI3K inhibitors, disrupt the PI3K/AKT pathway, crucial for cell survival and proliferation. This disruption could lead to the inhibition of LOC623272 by altering intracellular signaling dynamics. Rapamycin and PP242, targeting the mTOR signaling pathway, modulate processes like protein synthesis and autophagy, which could indirectly affect the function of LOC623272. Torin 1 also targets mTOR, affecting both mTORC1 and mTORC2 complexes, potentially impacting the protein's functional state through changes in cellular growth and survival.
Inhibitors like PD98059, U0126, Selumetinib, and PD0325901 target the MAPK/ERK pathway. By disrupting MEK and subsequently the MAPK/ERK signaling, these inhibitors could lead to changes in gene expression and cellular differentiation processes that might indirectly affect LOC623272. SB203580 and SP600125, inhibiting p38 MAPK and JNK respectively, might inhibit the protein by altering cellular stress responses and apoptotic pathways. Dactolisib, with dual inhibitory action on PI3K and mTOR pathways, represents a broader approach, potentially leading to the inhibition of LOC623272 by changing cellular dynamics related to proliferation and survival. These chemicals, through their targeted action on specific signaling pathways, collectively contribute to the potential functional inhibition of LOC623272, demonstrating the complex interplay of cellular signaling networks.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, might disrupt the PI3K/AKT pathway, potentially inhibiting LOC623272 by altering signals for cellular survival and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTORC1 inhibitor in the mTOR signaling pathway, could indirectly affect LOC623272 by modulating protein synthesis and autophagy. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor in the MAPK/ERK pathway, could indirectly inhibit LOC623272 by disrupting cell differentiation and proliferation signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, targeting p38 MAPK in the MAPK pathway, might potentially inhibit LOC623272 by altering cellular stress responses and inflammatory pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, inhibiting MEK1/2 in the MAPK/ERK pathway, might affect LOC623272 by changing cell differentiation and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, could inhibit LOC623272 by influencing cellular survival and metabolism within the PI3K/AKT pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125, a JNK inhibitor in the MAPK pathway, could inhibit LOC623272 by modulating cellular stress responses and apoptotic pathways. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242, a selective mTOR inhibitor, might affect LOC623272 by altering growth and survival processes within the mTOR signaling pathway. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
BEZ235, inhibiting PI3K/mTOR pathways, could lead to the inhibition of LOC623272 by altering cellular proliferation and survival dynamics. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib, a MEK1/2 inhibitor, could inhibit LOC623272 by impacting cell growth and differentiation within the MAPK/ERK pathway. |